Peptides for hormone imbalance and brain chemistry: what the evidence says
Quick answer
The creator received injections of LL-37, BPC-157, and TB-500 at a clinic while managing self-reported symptoms including brain fog, skin rashes, and mood instability following possible mycotoxin exposure. She declined a prescribed SSRI and is pursuing hormone specialist evaluation despite a normal hormone panel, attributing her symptoms to a unified hormonal pathway shared by mold illness, trauma, and psychiatric diagnoses. None of the three peptides she received carry FDA approval for any of the conditions she describes, and the clinical evidence supporting their use in this context is limited to early-phase or animal research.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @howtostaypretty actually say?
The creator describes getting injected with LL-37, BPC-157, and TB-500 at a clinic, then frames nearly every psychiatric and neurological condition, including anxiety, depression, bipolar disorder, and mold sickness, as ultimately rooted in hormone imbalance that then disrupts brain chemistry. "No matter what we're talking about, we're always going back to brain chemistry and always going back to hormones," she says. She also dismisses a normal hormone panel from her doctor, rejects a Prozac prescription, and describes SSRIs as simply giving you "more of the hormone that makes your brain run properly."
The core argument is that mold exposure, trauma, and bad environments all share a common pathway through hormones to produce psychiatric symptoms. It's an oversimplified but not entirely made-up idea, and the framing matters enormously for how people watching this make decisions about their own care.
Does the science back this up?
Partially, and with important caveats the video skips entirely. Mycotoxin exposure from certain mold species has been associated with neuroendocrine disruption in some studies, but the evidence is far from the clean causal chain she's describing.
A 2013 review by Crago et al. in the Archives of Environmental and Occupational Health found associations between water-damaged building exposure and symptoms including cognitive impairment and fatigue, but establishing a direct hormonal mechanism remains difficult. Separately, the HPA axis, which governs cortisol release, is genuinely affected by chronic stress, trauma, and PTSD (Yehuda et al., 2015, Biological Psychiatry). So trauma affecting hormones affecting brain function is a real pathway, just not the tidy universal one she presents.
Where the logic breaks down is in flattening all psychiatric diagnoses into a single hormonal explanation. Bipolar disorder, for instance, has a strong genetic architecture. A 2021 genome-wide association study in Nature Genetics identified over 60 loci linked to bipolar risk. Cortisol dysregulation plays a role in some cases, but it is not the root cause in any settled scientific sense.
What did they get wrong (or right)?
She gets partial credit for recognizing that the HPA axis connects stress, environment, and mood. That is real physiology. Chronic mold exposure producing systemic inflammation that affects mood and cognition? Plausible. Trauma dysregulating cortisol and contributing to depression and anxiety? Well-documented.
But three things here are genuinely wrong or reckless. First, dismissing a normal hormone panel because a specialist might find something different is not unreasonable on its face, but framing standard psychiatric care as a dead end while implying peptide injections are the real solution is a problem. Second, her description of Prozac, "all it does is give you more of the hormone that makes your brain run properly," is just incorrect. SSRIs work primarily by blocking serotonin reuptake at the synapse. Serotonin is a neurotransmitter, not a hormone, and the mechanism is substantially more complex than a simple top-up. Third, LL-37 is an antimicrobial peptide being studied in preclinical and early-phase research. Injecting it based on a mold-sickness self-diagnosis, at a clinic, without discussing its actual evidence base, is not something the current literature supports as standard of care.
What should you actually know?
If you are dealing with brain fog, mood instability, or suspect mold exposure, there are legitimate clinical pathways worth knowing about, and they do not require rejecting conventional medicine entirely.
- Mold-related illness is real but contested in its scope. Clinicians disagree on which symptoms qualify and how to diagnose it. The American Academy of Allergy, Asthma and Immunology has noted that the term "toxic mold syndrome" is not supported by current evidence as a distinct diagnosis.
- BPC-157 and TB-500 have shown tissue-repair and anti-inflammatory effects in rodent studies, but human clinical trial data is limited. Neither has FDA approval for any indication.
- LL-37 has antimicrobial and immunomodulatory properties studied in wound healing contexts. Its use as an injection for mold-related symptoms is not supported by published clinical evidence.
- If a standard hormone panel came back normal and symptoms persist, a second opinion from an endocrinologist is reasonable. That is different from concluding the entire testing framework is wrong.
- Rejecting an SSRI prescription is a personal choice, but the reasoning here, that Prozac just gives you a hormone, gets the pharmacology wrong and could discourage people from a treatment that has substantial evidence behind it for the conditions she mentions.
The bottom line
This video gestures at real biology but oversimplifies it into a framework that conveniently explains everything and, just as conveniently, points toward peptide therapy as the answer. The creator seems to genuinely believe what she is saying, and some of it has a foundation in real science. But the leaps from mold exposure to universal hormone theory to dismissing psychiatric diagnoses and standard pharmacology are significant. Watch this with a skeptical eye, and loop in a physician before drawing any conclusions about your own brain chemistry.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
BPC-157 access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptides for hormone imbalance and brain chemistry: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
beta-Thymosins
Background source for thymosin biology and tissue-repair mechanisms.
PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
BPC-157 is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this bpc-157 video claims cluster
Best for searchers trying to separate BPC-157 research signals from overconfident recovery claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator received injections of LL-37, BPC-157, and TB-500 at a clinic while managing self-reported symptoms including brain fog, skin rashes, and mood instability following possible mycotoxin exposure.
FormBlends verdict
The creator received injections of LL-37, BPC-157, and TB-500 at a clinic while managing self-reported symptoms including brain fog, skin rashes, and mood instability following possible mycotoxin exposure. She declined a prescribed SSRI and is pursuing hormone specialist evaluation despite a normal hormone panel, attributing her symptoms to a unified hormonal pathway shared by mold illness, trauma, and psychiatric diagnoses. None of the three peptides she received carry FDA approval for any of the conditions she describes, and the clinical evidence supporting their use in this context is limited to early-phase or animal research.
Patient-safe next step
Compare the claim with the BPC-157 guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator received injections of LL-37, BPC-157, and TB-500 at a clinic while managing self-reported symptoms including brain fog, skin rashes, and mood instability following possible mycotoxin exposure. She declined a prescribed SSRI and is pursuing hormone specialist evaluation despite a normal hormone panel, attributing her symptoms to a unified hormonal pathway shared by mold illness, trauma, and psychiatric diagnoses. None of the three peptides she received carry FDA approval for any of the conditions she describes, and the clinical evidence supporting their use in this context is limited to early-phase or animal research.
- BPC-157 and TB-500 have shown anti-inflammatory and tissue-repair effects in rodent models, but as of 2024 neither has completed Phase 3 human clinical trials for any indication, including mold-related illness or mood disorders.
- LL-37 is an antimicrobial peptide studied primarily in wound healing and infection contexts. There is no published clinical trial supporting its injection for mycotoxin-related neurological symptoms.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- BPC-157 decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the BPC-157 guide, cost path, safety notes, and provider review before acting.
Review BPC-157What You'll Learn
- BPC-157 and TB-500 have shown anti-inflammatory and tissue-repair effects in rodent models, but as of 2024 neither has completed Phase 3 human clinical trials for any indication, including mold-related illness or mood disorders.
- LL-37 is an antimicrobial peptide studied primarily in wound healing and infection contexts. There is no published clinical trial supporting its injection for mycotoxin-related neurological symptoms.
- A 2021 Nature Genetics genome-wide association study (Mullins et al.) identified over 60 genetic loci linked to bipolar disorder, making a purely hormonal explanation for the condition scientifically incomplete.
- Serotonin is classified as a monoamine neurotransmitter, not a hormone in the conventional sense. SSRIs do not simply increase serotonin levels but alter reuptake dynamics and trigger downstream neuroplastic changes over weeks.
- Mycotoxin-related illness is a legitimate area of research, but the American Academy of Allergy, Asthma and Immunology has stated that 'toxic mold syndrome' is not supported as a distinct clinical diagnosis by current evidence.
- A normal hormone panel from a primary care physician does not rule out all endocrine dysfunction, and a referral to an endocrinologist can be clinically appropriate, but this is different from concluding that standard diagnostic frameworks are fundamentally wrong.
- Placebo response following any injection procedure can produce real, measurable short-term symptom changes. Feeling better immediately after a peptide injection does not confirm the treatment mechanism the provider claims.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
howtostaypretty · TikTok creator
12.6K views on this video
Took Peptides #LL-37 #BPC-157 #TB-500 Everything is going back to the same thing - total hormone imbalance = brain chemistry off and not functioning #brainchemistry #hormoneimbalance#brainfunction#brain#moldsickness#mold#ptsd
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by howtostaypretty, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.